ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 0647 • ACR Convergence 2022

    Transcriptomic Analysis of Lupus Nephritis Kidneys Identifies Molecular Endotypes

    Kathryn Kingsmore Allison1, Sneha Shrotri1, Prathyusha Bachali2, Nan Shen3, Amrie Grammer4 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2AMPEL BioSolutions, Redmond, WA, 3Shanghai Jiang Tong University School of Medicine, Shanghai, China, 4AMPEL LLC, Charlottesville, VA

    Background/Purpose: Predicting the course or response to treatment of lupus nephritis (LN) from standard renal biopsies is problematic. We, therefore sought to understand the molecular…
  • Abstract Number: 1347 • ACR Convergence 2022

    Poor Health-Related Quality of Life in Patients with Lupus Nephritis

    Cristina Arriens1, Janice Ma2, Konrad Pisarczyk2, Richard Leff3, Kiruthi Palaniswamy4 and Li Long4, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Maple Health Group, LLC, New York, NY, 3Kezar Life Sciences, South San Francisco, CA, 4Kezar Life Sciences, Inc., South San Francisco, CA

    Background/Purpose: Lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE) associated with considerable morbidity that has a devastating impact…
  • Abstract Number: 1697 • ACR Convergence 2022

    Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE

    Anne Troldborg1, Mads Lamm Larsen1, Erik J.M. Toonen2, Lisa Hurler3, Zoltan Prohaszka3, László Cervenak3, Annette Gudmann Hansen4 and Steffen Thiel4, 1Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 2Hycult Biotech, Arnhem-Nijmegen, Netherlands, 3Semmelweis University, Budapest, Hungary, 4Aarhus University, Aarhus, Denmark

    Background/Purpose: In systemic lupus erythematosus (SLE), the complement system is activated and commonly thought to occur through the classical pathway (CP) [1]. However, our previous…
  • Abstract Number: 2222 • ACR Convergence 2022

    Lupus Clinical Flares in Patients with Gut Pathobiont Blooms Share a Novel Peripheral Blood Transcriptomic Immune Activation Profile

    Gregg Silverman1, Macintosh Cornwell1, Peter Izmirly1, Mala Masson1, Jill Buyon1, Doua Azzouz2 and Kelly Ruggles1, 1NYU Grossman School of Medicine, New York, NY, 2NYU Gross School of Medicine, New York, NY

    Background/Purpose: SLE is an inflammatory condition associated with hyperactivation of the immune system, with mounting evidence that imbalances in the gut microbiota communities are common.…
  • Abstract Number: 0356 • ACR Convergence 2022

    Early Reductions in Proteinuria with Voclosporin Treatment Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials

    Anca Askanase1, Lucy Hodge2, Vanessa Birardi3 and Henry Leher3, 1Columbia University Medical Center, New York, NY, 2Aurinia Pharmaceuticals, Seattle, WA, 3Aurinia Pharmaceuticals Inc, Rockville, MD

    Background/Purpose: Voclosporin, a novel calcineurin inhibitor, is approved for the treatment of adults with lupus nephritis in combination with background immunotherapy and was successfully tested…
  • Abstract Number: 0648 • ACR Convergence 2022

    Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients

    Edmund Chang1, Julian Low2, Ellen Cahir-McFarland2, Henk-Andre Kroon2, Yaisa Andrews-Zwilling2, Ted Yednock2 and Ann Mongan2, 1Annexon Biosciences, Brisbane, CA, 2Annexon Biosciences, South San Francisco, CA

    Background/Purpose: In LN, excess immune complexes lead to nephrotic deposition of C1q and C4d, the latter of which has been correlated with circulating C4d and…
  • Abstract Number: 1360 • ACR Convergence 2022

    Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide

    Christine Wang1, Rebecca Sadun2, Wenru Zhou3, Kristen Miller3, Claire Palmer3, Stacy P Ardoin4, Christine Bacha5, Emily Hause6, Joyce Hui-Yuen7, Nicole Ling8, Maria Pereira9, Meredith Riebschleger10, Kelly Rouster-Stevens11, Aliese Sarkissian12, Julia Shalen13, William Soulsby14, Marinka Twilt15, Eveline Wu16, Laura Lewandowski17, Scott Wenderfer18 and Jennifer Cooper19, 1Children's Hospital of Colorado/University of Colorado, Denver, CO, 2Duke University, Durham, NC, 3University of Colorado School of Medicine, Aurora, CO, 4Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, 5Nationwide Children's Hospital, Columbus, OH, 6University of Minnesota, Minneapolis, MN, 7Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, 8UCSF, San Francisco, CA, 9Baylor College of Medicine, Houston, TX, 10University of Michigan, Ann Arbor, MI, 11Emory University/Children's Healthcare of Atlanta, Atlanta, GA, 12University of North Carolina at Chapel Hill, Chapel Hill, NC, 13Johns Hopkins University, Baltimore, MD, 14University of California, San Francisco, San Francisco, CA, 15Alberta Children's Hospital, Calgary, AB, Canada, 16University of North Carolina, Chapel Hill, NC, 17NIAMS, NIH, Bethesda, MD, 18British Columbia Children's Hospital, Vancouver, BC, Canada, 19University of Colorado/Children's Hospital Colorado, Denver, CO

    Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
  • Abstract Number: 1716 • ACR Convergence 2022

    The Transcriptomic Landscape of Nephritic Kidneys Reveals Mechanisms for End Organ Resistance to Damage in Lupus-prone Mice

    Andrea Daamen1, Hongyang Wang2, Prathyusha Bachali3, Shu Man Fu2, Amrie Grammer4 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2University of Virginia, Charlottesville, VA, 3AMPEL BioSolutions, Redmond, WA, 4AMPEL LLC, Charlottesville, VA

    Background/Purpose: Pathologic inflammation is a major driver of kidney damage in lupus nephritis (LN), but the immune mechanisms of disease progression and risk factors for…
  • Abstract Number: PP13 • ACR Convergence 2022

    How Becoming Engaged in My Care with Specialized Tools and Support Helped Me Find My Personal Lupus Triggers and Regain Control of My Health

    Tonya Hinton-Green, Philadelphia, PA

    Background/Purpose: My story begins in the ER where I was diagnosed with lupus right after my 22nd birthday.For the next 25 years I went from…
  • Abstract Number: 0059 • ACR Convergence 2022

    Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus

    Kenneth Kalunian1, Janice Ma2, Konrad Pisarczyk2, Richard Leff3, Kiruthi Palaniswamy4 and Li Long4, 1University of California San Diego, La Jolla, CA, 2Maple Health Group, LLC, New York, NY, 3Kezar Life Sciences, South San Francisco, CA, 4Kezar Life Sciences, Inc., South San Francisco, CA

    Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE), which develops in about one-third of SLE patients within…
  • Abstract Number: 0357 • ACR Convergence 2022

    Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

    Hans-Joachim Anders1, Raymond Federico2, Vanessa Birardi3 and Henry Leher3, 1University of Munich, Munich, Germany, 2Aurinia Pharmaceuticals, Inc., Victoria, BC, Canada, 3Aurinia Pharmaceuticals Inc, Rockville, MD

    Background/Purpose: Pooled data from the Phase 2 AURA-LV and Phase 3 AURORA 1 studies demonstrated that adding voclosporin, a novel calcineurin inhibitor, to mycophenolate mofetil…
  • Abstract Number: 0650 • ACR Convergence 2022

    The Association of Urinary C9 to CD59 Ratio with Tubulointerstitial Fibrosis in Lupus Nephritis

    Shudan Wang1, Masako Suzuki2, Daming Shao3, Muhammad Hamza Bukhari4, Brianna Lally5, Michael Belmont6, Jennifer Aguilan2, Simone Sidoli2, Anna Broder7 and J. Michelle Kahlenberg8, 1Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, 4Norwalk Hospital/Yale University, Norkwalk, VA, 5University of Wisconsin Hospitals and Clinics, Madison, WI, 6NYU Grossman School of Medicine, New York, NY, 7Hackensack University Medical Center, Hackensack, NJ, 8University of Michigan, Ann Arbor, MI

    Background/Purpose: Animal and human studies suggest that terminal complement activation has a pathogenic role in tubulointerstitial fibrosis, which is a strong predictor of irreversible kidney…
  • Abstract Number: 1371 • ACR Convergence 2022

    Juvenile Onset SLE in India-Data from a Multi-institutional Inception (INSPIRE) Cohort of Systemic Lupus Erythematosus

    Amita Aggarwal1, Liza Rajasekhar2, Parasar Ghosh3, Ashish J Mathew4, Chengappa Kavadichanda5, Vineetha Shobha6, Ranjan Gupta7, Saumya Ranjan Tripathy8, Manish Rathi9, Avinash Jain10 and Able Lawrence1, 1Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Nizam's Institute of Medical Sciences, Madhapur, India, 3Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, 4Rigshospitalet, Copenhagen, Denmark, 5JIPMER, Pondicherry, Puducherry, India, 6St. John’s Medical College Hospital, Bangalore, India, 7All India Institute of Medical Sciences, New Delhi, India, 8SCB medical college, Cuttack, India, 9PGIMER Chandigarh, Chandigarh, India, 10SMS Medical College, Lucknow, India

    Background/Purpose: Most Lupus cohorts across the globe have poor representation of patients from South Asia who are ethnically different. We explored the clinical features and…
  • Abstract Number: 1717 • ACR Convergence 2022

    Deficiency of IL-23 Receptor in Podocytes of MRL/lpr lupus-prone Mice Abrogates the Development of Lupus Nephritis Despite IgG Deposition in the Glomeruli

    Afroditi Boulougoura1, Hao Li1, Rhea Bhargava1, Wenliang Pan1, Abhigyan Satyam1, Isaac Stillman2 and George Tsokos1, 1Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 2Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Background/Purpose: Interleukin 23 (IL-23) is involved in the pathogenesis of systemic lupus erythematosus (SLE). IL-23 is elevated in the sera of patients with active SLE…
  • Abstract Number: PP26 • ACR Convergence 2022

    Chronically Catherine: A Sex and the City-Inspired Autobiographical Column for Disabled Young Adults on Subjects We Really Care About – Like Disabled Dating and How Hot Cheetos Saved My Life

    Catherine Ames1, Courtney Wells2 and Kristine Carandang1, 1Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, 2University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN

    Background/Purpose: What if Carrie Bradshaw, sex advice columnist, fashionsta, and all around icon from Sex and the City were chronically ill? Or disabled? That's the…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology